PF 04217903 mesylate
Cat. No. 4239
Chemical Name: 4-[1-(6-Quinolinylmethyl)-1H-1,2,3-
Biological ActivityHighly selective, high affinity MET inhibitor (Ki = 6-7 nM against wild type c-Met). Displays >1000-fold selectivity for c-Met over a panel of 208 kinases.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Eder et al (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin.Cancer Res. 15 2207. PMID: 19318488.
Timofeevski et al (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48 5339. PMID: 19459657.
Underiner et al (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med.Chem. 10 7. PMID: 20015007.
Cui et al (2012) Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J.Med.Chem. 55 8091. PMID: 22924734.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PF 04217903 mesylate, supplier, pfizer, PF04217903, c-met, met, mesenchymal, epithelial, transition, factor, hgfr, receptors, tyrosine, kinase, rtk, inhibitors, anticancer, selective, MET Receptor Inhibitors
Find multiple products by catalog number
New Products in this Area
Potent VEGFR inhibitor; also aromatase inhibitorPF 06463922
High affinity and selective ALK and ROS1 inhibitor6bK
Insulin degrading enzyme (IDE) inhibitorCrizotinib
Potent c-MET/ALK inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.